Nina Shah, MD

Cancer.Net Associate Editor: Myeloma
University of California San Francisco, San Francisco, CA

Dr. Nina Shah is a Professor of Clinical Medicine in the Division of Hematology-Oncology at University of California San Francisco. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is one of the lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine clinical trial for people with myeloma. Additionally, she is the institutional principal investigator for numerous cellular therapy and immunotherapy protocols.

Dr. Shah is also interested in outcomes research for people with myeloma who are undergoing autologous stem cell transplantation and led a randomized clinical trial to determine the impact of stem cell dose on symptoms in this patient population. She has published on the link between patient-reported outcomes and physical testing in this clinical context and is conducting a study to investigate digital life coaching during transplant recovery. She is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT). She also serves as a Co-Chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a member of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.

View current ASCO disclosurehere.

Last updated: October 2021